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Correspondence
To the Editor-Carpentier et al. [1] recently reported that combined determination of early-antigen (EA) IgG titers and of Epstein-Barr virus (EBV) DNA loads in peripheral-blood mononuclear cells (PBMCs) could be useful as prognosis markers to evaluate the risk of development of posttransplantation lymphoproliferative disease (PTLD). The incidence of EBV-related PTLD has been reported to vary from 1% to 33%, with a mortality rate as high as 25%-45% in pediatric recipients of organ transplants [2, 3] . The detection of a high EBV DNA load in blood usually precedes PTLD, but not all transplant recipients with a high EBV DNA load will develop PTLD. Various EBV DNA-load threshold values above which the risk for PTLD increases have been described by teams using different quantitative techniques and studying different transplant-recipient populations [4] [5] [6] [7] . However, the specificity of these threshold values for the assessment of the risk of development of PTLD remains low. The description of an additional marker for the prediction of EBV-related PTLD is needed, and therefore Carpentier et al.'s data are interesting.
In our center, we follow children who receive kidney, liver, small-bowel, and heart transplants. For PTLD screening, an in-house semiquantitative DNA polymerase chain reaction (PCR)was performed on PBMCs between 1994 and 2002, whereas an in-house real-time PCR has been performed on whole blood since 2002. Testing for EBV serologic markers, including that used to test for EA IgG (ETI-EA-G; DiaSorin), has also regularly been performed in the follow-up of these chil- dren. Beginning with cases from 1995, we retrospectively searched our database to identify transplant-recipient children who had high EBV DNA loads (defined as either 11000 genome copies/10 5 PBMCs or 110,000 copies/mL of whole blood) and who regularly had been tested for EA IgG. Thirty-nine children fulfilled these criteria, and 19 were selected for this study because follow-up was complete enough to allow the results to be reliably interpreted; the results for these 19 children are presented in table 1. EBV serologic status before transplantation was negative in 12 of the 19 children and was positive in the other 7. PTLD occurred in 10 children-after primary infection in 7 cases and after EBV reactivation in 3 cases; in 9 of these 10 children, the results of tests for EA IgG were negative at the time of PTLD; in 4 of these 9 children, the results remained negative during the entire follow-up, and the appearance of EA IgG was delayed (53-255 weeks) in the other 5. One child with PTLD (patient 6) had a high level of EA IgG concomitantly with both the first high positive result of PCR and the occurrence of PTLD and before she received any immunoglobulins intravenously. It is worth noting that this child had an uncommon PTLD presentation, with proliferation of T cell lineages in the skin and adenoids [8, 9] . In 6 of the 9 children who did not develop PTLD, the results of tests for EA IgG were positive concomitantly with the first high EBV DNA load, and they were positive 3-53 weeks after the first high EBV DNA load in the other 3. Therefore, with regard to the development of PTLD, the results in our series of transplantrecipient patients show that a high EBV DNA load concomitant with negative results of tests for EA IgG has a positive predictive value of 75% and a negative predictive value of 86%. Therefore, our results partly confirm those of Carpentier et al., in that testing for EA IgG, in association with quantification of EBV DNA loads in blood, may allow more-accurate screening of patients at risk for PTLD. However, difficulties will remain: first, false-positive results of tests for EA IgG could occur in transplantrecipient patients treated with immunoglobulins intravenously, and this possibility must be evaluated; second, results of tests for EA IgG might also be correctly positive in some children with uncommon PTLD with proliferation of T cell lineages; and, finally, in pretransplant seronegative children, a negative result of a test for EA IgG lacks specificity in the prediction of PTLD, particularly when the latter occurs early after transplantation. Indeed, in these cases, the first positive result of a test for EBV PCR is often detected within the first 3 weeks after transplantation of an EBVpositive organ, and the EBV DNA load in blood is often high, whereas the results of tests for EA IgG are always negative: in our study, for example, 7 children with primary EBV infection (patients 1-4, 7, 12, and 13) had high EBV DNA loads early after transplantation and concomitantly negative results of tests for EA IgG. It was impossible, at this early stage of the infection, to distinguish between the 5 children who rapidly developed PTLD and the 2 who did not.
In conclusion, testing for EA IgG will probably help in the interpretation of high EBV DNA loads in pediatric recipients of organ transplants; however, the predictive value of these 2 tests done simultaneously must be analyzed prospectively. Reply to Leruez-Ville et al.
To the Editor-Although our study used a small study cohort, my colleagues and I had hoped that, in publishing our initial findings, we might encourage other investigators to expand available data and, hence, to support or disprove our assertion that a high peripheral-blood EpsteinBarr virus (EBV) DNA load coupled with a second marker-namely, an absent or weak EBV early-antigen (EA) serologic response-has prognostic value for posttransplantation lymphoproliferative disease (PTLD). The data provided by Leruez-Ville et al. [1] largely agree with the results of our recently published study [2] . After careful analysis of their results, we note that Leruez-Ville et al. have raised several concerns with regard to the use of the interpretation of EA serology as a second marker in the diagnosis of PTLD. Leruez-Ville et al. point out that, in their study cohort of 19 patients, 1 was diagnosed with a rare T cell tumor of the skin. This patient showed strong IgG seroreactivity to EA, concurrent with a high EB viral load, an observation that runs counter to our claim, indicating a possible lack of correlation between these 2 viral markers in atypical presentations of PTLD. It is noteworthy, however, that Leruez-Ville et al.'s findings for the B cell PTLDs in their cohort are in line with our results.
Another concern raised by Leruez-Ville et al. is the possibility of false-positive EA serotiters after passive transfer of EA IgG antibodies to patients treated with intravenous immune globulin (IVIG) for cytomegalovirus prophylaxis in cases of mismatched donor/recipient pairs. We had considered this possibility and consequently sought to test patient sera after infusion of IVIG, but we found no titers with detectable EA IgG. Moreover, we examined the timing of the appearance of EA IgG in the 3 patients (i.e., patients 7, 9, and 10 in [2, table 2]) in our study cohort who had been treated with IVIG. Surprisingly, in the development of significant titers of EA IgG, these patients showed a mean additional delay of 24.8 weeks, compared with the 11 patients not treated with IVIG.
Leruez-Ville et al. also observe that their EBV-negative patients infected during the early posttransplantation period (i.e., 0-10 weeks) showed high EB viral loads but no detectable EA IgG. Seven of their patients-namely, patients 1-4, 7, 12, and 13-belong to this category, and 5 of these 7 developed PTLD. After analysis based on the viral-load and EA-serology tests, Leruez-Ville et al. note that the 2 patients who did not develop PTLD could not be distinguished from the 5 who did develop PTLD, and they therefore conclude that absence of EA IgG in patients with a high viral load is not an absolutely reliable predictor of the occurrence of PTLD. On their point that the use of the EA-serology test as a second marker has limitations, we agree with Leruez-Ville et al. Nonetheless, the salient message of both studies is that the positive predictive value of the EA-serology test used in conjunction with the viral-load test, although not 100%, is still considerably higher than that of the viral-load test alone.
Last, Leruez-Ville et al. call for a prospective study to further analyze the predictive value of EA serology in patients with a high viral load. Scientifically, we concur; however, we feel that it would be more practical to perform retrospective studies. Large serum banks from major transplantation centers should allow for ready analysis of viral load and EA serology of transplant-recipient patients with and without PTLD. Such an undertaking would add some much-needed statistical power to the existing data, thereby clarifying the importance of EA serology as a second marker for the prognosis of PTLD.
